Revenue growth remains highly volatile and dependent on milestone payments, as evidenced by the 71.5% year-over-year increase in 2026Q1 while operating margins remain deeply negative at -2.6%.
| Sales/Revenue | 55.54M | 48.47M | 114.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -55.42% | -57.74% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 232K | 1M | 0 | 0 | 0 | 0 | 4.27M | 3.09M | 297K | 0 | 0 |
| COGS % of Revenue | - | 2.07% | - | - | - | - | - | - | - | - | - |
| Gross Profit | 55.3M | 47.47M | 114.7M | 0 | 0 | 0 | -4.27M | -3.09M | -297K | 0 | 0 |
| Gross Margin % | 99.58% | 97.93% | 100% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -58.61% | - | - | - | 100% | -38.17% | -940.07% | - | - | - |
| Operating Expenses | 234.09M | 210.72M | 174.62M | 183.76M | 218.59M | 216.12M | 206.31M | 182.54M | 99.33M | 1.15M | 83K |
| OpEx % of Revenue | - | 434.74% | 152.24% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 47.72M | 37.63M | 36.13M | 38.45M | 47.61M | 45.78M | 48.32M | 39.14M | 44.05M | 262K | 83K |
| SG&A % of Revenue | - | 77.64% | 31.5% | - | - | - | - | - | - | - | - |
| Research & Development | 186.6M | 174.09M | 138.49M | 135.3M | 170.92M | 170.27M | 158M | 143.4M | 55.28M | 891K | 0 |
| R&D % of Revenue | - | 359.17% | 120.74% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -227K | -1M | 0 | 10M | 65K | 75K | 0 | 5.83M | 316K | 0 | 0 |
| Operating Income | -178.78M | -163.25M | -59.92M | -183.76M | -218.59M | -216.12M | -210.58M | -186.14M | -148.99M | -6.65M | -83K |
| Operating Margin % | -321.92% | -336.81% | -52.24% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -172.46% | 67.39% | 15.94% | -1.14% | -2.63% | -13.13% | -24.93% | -2139.49% | -7915.66% | - |
| EBITDA | -178.11M | -162.25M | -55.77M | -179.37M | -214.16M | -210.96M | -206.31M | -183.05M | -148.7M | -5.5M | 0 |
| EBITDA Margin % | -320.7% | -334.74% | -48.62% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -247.44% | -190.94% | 68.91% | 16.24% | -1.52% | -2.25% | -12.71% | -23.1% | -2603.56% | - | - |
| D&A (Non-Cash Add-back) | 678K | 1M | 4.15M | 4.38M | 4.43M | 5.17M | 4.27M | 3.09M | 297K | 1.15M | 83K |
| EBIT | -170.44M | -163.25M | -44.12M | -166.31M | -215.5M | -214.56M | -230.69M | -182.54M | -146.96M | -6.65M | -83K |
| Net Interest Income | -8.97M | -9.02M | -9.74M | -11.51M | -12.3M | -18.68M | -9.22M | 0 | 1.71M | 0 | 0 |
| Interest Income | 2.03M | 1.97M | 1.78M | 2M | 1.58M | 761K | 3.44M | 0 | 1.72M | 0 | 0 |
| Interest Expense | 11M | 10.99M | 11.52M | 13.51M | 13.88M | 19.44M | 12.67M | 0 | 12K | 118K | 0 |
| Other Income/Expense | -1.7M | -7.21M | 4.28M | 3.94M | -10.79M | -17.88M | -32.78M | 5.83M | 2.02M | -118K | 0 |
| Pretax Income | -180.48M | -170.46M | -55.63M | -179.82M | -229.38M | -234M | -243.36M | -180.31M | -146.97M | -6.77M | -83K |
| Pretax Margin % | -324.98% | -351.67% | -48.5% | - | - | - | - | - | - | - | - |
| Income Tax | -88K | -88K | 893K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.05% | 0.05% | -1.61% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -180.4M | -170.37M | -56.53M | -179.82M | -229.38M | -234M | -243.36M | -180.82M | -146.97M | -6.77M | -83K |
| Net Margin % | -324.82% | -351.49% | -49.28% | - | - | - | - | - | - | - | - |
| Net Income Growth % | -252.07% | -201.39% | 68.56% | 21.61% | 1.98% | 3.84% | -34.59% | -23.03% | -2070.57% | -8057.83% | - |
| Net Income (Continuing) | -180.4M | -170.37M | -56.53M | -179.82M | -229.38M | -234M | -243.36M | -180.31M | -146.97M | -6.77M | -83K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.77 | -0.75 | -0.25 | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | -0.01 |
| EPS Growth % | -229.17% | -200% | 78.81% | 58.45% | 14.71% | 9.26% | -11.21% | -35.8% | -800% | - | - |
| EPS (Basic) | - | -0.75 | -0.25 | -0.80 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | -0.01 |
| Diluted Shares Outstanding | 234.14M | 228.52M | 226.23M | 225.57M | 84.57M | 74.84M | 68.51M | 54.74M | 60.4M | 24.83M | 9.16M |
| Basic Shares Outstanding | 234.14M | 228.52M | 226.23M | 225.57M | 84.57M | 74.84M | 68.51M | 54.74M | 60.4M | 24.83M | 9.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial funding shortfall
As reported in financial statements, GOSS's revenue trajectory remains entirely dependent on non-recurring milestone payments, evidenced by the 71.5% year-over-year growth in 2026Q1, which masks the absence of any sustainable commercial product sales or predictable organic growth patterns within the company's current clinical-stage business model.
The revenue profile is inherently lumpy and tied to specific partnership milestones rather than market-driven demand. Investors should monitor the sustainability of these payments, as they appear to be the primary mechanism for funding operations in the absence of a commercialized asset.
Based on reported figures, GOSS maintains a high-burn cost structure where R&D expenses consistently exceed $30 million per quarter, reaching $43.1 million in 2026Q1, which underscores the firm's heavy reliance on external capital to sustain its ongoing Phase 3 clinical development programs.
The concentration of spending in R&D reflects the company's singular focus on seralutinib. This expense discipline is secondary to the necessity of trial completion, suggesting that cost management is currently subordinate to the urgency of achieving clinical milestones.
According to recent SEC filings, GOSS exhibits significant negative operating leverage, with operating losses consistently hovering near $40 million to $49 million per quarter, indicating that the company has yet to achieve the scale required to offset its substantial fixed overhead and clinical trial expenditures.
The lack of operating leverage is expected for a pre-commercial biotech firm, but the persistence of these losses highlights the extreme sensitivity of the firm's valuation to clinical outcomes. Without a commercial product, there is no evidence of a path toward operational self-sufficiency in the near term.
As indicated by the company's reported cash and equivalents of $37.7 million against quarterly operating losses often exceeding $40 million, GOSS faces a precarious liquidity position that may necessitate dilutive financing or further strategic asset compromises to maintain its current clinical development trajectory.
The mismatch between current cash reserves and the burn rate suggests that the company is approaching a critical funding inflection point. Market participants should remain cautious regarding the potential for equity dilution, which appears increasingly likely given the current pace of capital consumption.
Quick answers to the most common questions about buying GOSS stock.
For fiscal year 2025, Gossamer Bio, Inc. (GOSS) reported total revenue of $48.5M.
Gossamer Bio, Inc. (GOSS) reported a net loss of $170.4M for the fiscal year ending 2025.
Gossamer Bio, Inc. (GOSS) reported an operating income of $-163.3M, resulting in an operating profit margin of -336.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Gossamer Bio, Inc. (GOSS) generated $47.5M in gross profit for the year, representing a gross profit margin of 97.9%. This demonstrates the company's core pricing power and production efficiency.